Inflammatory Bowel Disease (IBD)
The challenges of IBD drug development
Intestinal inflammation is among the most prevalent health indications in the western world, comprising a range of diseases, including inflammatory bowel disease (IBD). Efficient treatments for IBD, however, are lacking.
Unfortunately, the exact mechanisms behind IBD are poorly understood owing to its multifactorial etiology; Studying such an intricate disease successfully can never be achieved with a simple culture system.
The complexity of the disease, combined with the lack of suitable models makes studying IBD and the development of preventative or therapeutic agents challenging.
Drug Development Partnerships
Watch our Roundtable Discussion on IBD